

Datasheet for ABIN7538785

SARS-CoV-2 Spike-, Membrane-, Envelope-, Nucleoprotein protein-VLP



[Go to Product page](#)

Overview

| | |
|---------------|--|
| Quantity: | 2 x 100 µg |
| Target: | SARS-CoV-2 Spike-, Membrane-, Envelope-, Nucleoprotein |
| Origin: | SARS Coronavirus-2 (SARS-CoV-2) |
| Source: | HEK-293 Cells |
| Protein Type: | VLP |
| Application: | ELISA, Immunoelectron Microscopy (IEM), Lateral Flow (LF), Nanoparticle Tracking Analysis (NTA), Western Blotting (WB) |

Product Details

| | |
|------------------------------|---|
| Purpose: | Set: VLP of SARS-CoV-2 (S+M+E+N) + Control VLP of SARS-CoV-2 (M+E+N) |
| Characteristics: | SARS-CoV-2 virus-like particles (VLP) were produced in HEK cells by co-expression of the spike-, membrane-, envelope- and nucleoprotein. The VLPs do not contain the viral genome, cannot replicate and are not infectious. |
| Purification: | Tangential flow filtration and polyethylene glycol precipitation |
| Components: | Set contains: G-0005-100UL and G-0004-100UL. |
| Biological Activity Comment: | active |

Target Details

| | |
|-------------|--|
| Target: | SARS-CoV-2 Spike-, Membrane-, Envelope-, Nucleoprotein |
| Background: | SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a coronavirus (genus: Betacoronavirus, subgenus: Sarbecovirus) that was identified as the cause of COVID-19 disease |

Target Details

in early 2020.

Application Details

| | |
|--------------------|---|
| Application Notes: | Applications: Immunogenic antigen, antigen for ELISA and Western blot, reference for rapid antigen tests. Western blot: 1-10 µg, ELISA: 1-5 µg/mL |
| Comment: | Virus-like Particles are multiprotein complexes that resemble a native virus, but lack the genetic information. Therefore, VLPs are safe to handle in numerous fields of applications. For example, VLPs can be applied as antigen in serological assays (e.g. ELISA), or serve as reference material to standardize the performance of different diagnostic tests (e.g. rapid antigen tests or ELISA). Due to the self-adjuvanting properties of VLPs is the most common application of VLPs the use as antigen for immunizations for vaccine development or antibody discovery campaigns. |
| Restrictions: | For Research Use only |

Handling

| | |
|------------------|--------------|
| Format: | Liquid |
| Concentration: | Lot specific |
| Buffer: | PBS |
| Storage: | -80 °C |
| Storage Comment: | - 80°C |